title: A randomized, placebo-controlled trial of sertraline for prophylactic treatment of highly recurrent major depressive disorder.
abstract: OBJECTIVE
  Previous antidepressant maintenance trials have used the same medication from acute through maintenance phases, confounding the interpretation of prophylactic effects. The purpose of this study was to determine whether sertraline prevents the recurrence of major depressive disorder among patients with recurrent depression who had been treated to remission with medications other than sertraline.
  
  
  METHODS
  Patients who had experienced at least three documented episodes of major depressive disorder within the last 4 years and who were currently in full remission were eligible. The last episode must have been treated for at least 4 months with any antidepressant except sertraline. For the initial single-blind placebo lead-in phase, 371 patients were included; 288 were included in the analyses for the 18-month double-blind phase in which patients were randomly assigned to sertraline (50 or 100 mg) or placebo (two capsules per day). Recurrence was defined as a depressive episode that fulfilled DSM-IV criteria or the appearance of symptoms that required the administration of another antidepressant treatment.
  
  
  RESULTS
  Sixty-one patients discontinued before the double-blind phase, including 33 who experienced a relapse. Out of the 288 who entered the double-blind prophylactic phase, 123 discontinued, including 65 for recurrences. Recurrences were significantly lower in the sertraline groups compared with placebo (sertraline, 50 mg: 16 [16.8%] of 95; sertraline, 100 mg: 16 [17.0%] of 94; placebo: 33 [33.3%] of 99). Patients treated with sertraline also had a significantly longer time until recurrence compared with placebo-treated patients.
  
  
  CONCLUSIONS
  Among remitted patients with a history of multiple depressive episodes, sertraline at a dose of either 50 or 100 mg/day prevented recurrences significantly more than did placebo.
authors.affiliation: Hôpital Fernand Widal, Assistance Publique Hôpitaux de Paris; Centre Hospitalier Régional Universitaire, Caen, France.
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Lépine
authors.forename: Vincent
authors.initials: V
authors.lastname: Caillard
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: Bisserbe
authors.forename: Sylvie
authors.initials: S
authors.lastname: Troy
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Hotton
authors.forename: Patrice
authors.initials: P
authors.lastname: Boyer
mesh_terms: D000328:Adult; D002985:Clinical Protocols; D003866:Depressive Disorder / Q000517:prevention & control* / Q000523:psychology; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D055502:Secondary Prevention; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D020280:Sertraline / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D010919:Placebos; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline